Press Releases

Biocon Biologics  /  Press Releases

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

  • Posted by: Biocon Biologics

Biocon Foundation & Department of Medical, Health & Family Welfare, Govt. of Karnataka Collaborate to Set Up Smart eLAJ Clinics in Karnataka

  • Posted by: Biocon Biologics

Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia

  • Posted by: Biocon Biologics

Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore Revenue Rises 32% at Rs 1092 Crore; EBITDA Increases 57% to Rs 324 Crore

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: Biocon Biologics

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon’s Proposed Biosimilar Trastuzumab Phase 3 Data

  • Posted by: Biocon Biologics

Biocon Features in Asia IP Elite 2016 List

  • Posted by: Biocon Biologics

Biocon’s Novel Diabetes Education Initiative for Medical Practitioners ‘ABIDE’ Awarded by RSSDI

  • Posted by: Biocon Biologics

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India

  • Posted by: Biocon Biologics
Share